After finishing at $5.36 in the prior trading day, Adma Biologics Inc (NASDAQ: ADMA) closed at $5.52, up 2.99%. In other words, the price has increased by $+0.16 from its previous closing price. On the day, 3400843 shares were traded. ADMA stock price reached its highest trading level at $5.57 during the session, while it also had its lowest trading level at $5.32.
Ratios:
Our goal is to gain a better understanding of ADMA by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 24.53 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 312.60. For the most recent quarter (mrq), Quick Ratio is recorded 1.69 and its Current Ratio is at 5.16. In the meantime, Its Debt-to-Equity ratio is 1.05 whereas as Long-Term Debt/Eq ratio is at 1.04.
On October 13, 2022, Mizuho started tracking the stock assigning a Buy rating and target price of $5.
Raymond James Upgraded its Outperform to Strong Buy on November 11, 2021, while the target price for the stock was maintained at $5.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 30 when Grossman Jerrold B bought 130,000 shares for $3.71 per share. The transaction valued at 482,144 led to the insider holds 443,265 shares of the business.
KWON YOUNG bought 25,000 shares of ADMA for $97,500 on Aug 24. The Director now owns 277,401 shares after completing the transaction at $3.90 per share. On Aug 22, another insider, Fong Bryant, who serves as the Director of the company, sold 1,433,304 shares for $3.87 each. As a result, the insider received 5,544,737 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADMA now has a Market Capitalization of 1.25B and an Enterprise Value of 1.34B. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.88 while its Price-to-Book (P/B) ratio in mrq is 9.23. Its current Enterprise Value per Revenue stands at 5.18 whereas that against EBITDA is 261.32.
Stock Price History:
Over the past 52 weeks, ADMA has reached a high of $5.72, while it has fallen to a 52-week low of $2.94. The 50-Day Moving Average of the stock is 5.00, while the 200-Day Moving Average is calculated to be 4.09.
Shares Statistics:
The stock has traded on average 2.28M shares per day over the past 3-months and 2.69M shares per day over the last 10 days, according to various share statistics. A total of 226.06M shares are outstanding, with a floating share count of 218.14M. Insiders hold about 4.15% of the company’s shares, while institutions hold 74.44% stake in the company. Shares short for ADMA as of Feb 15, 2024 were 6.15M with a Short Ratio of 2.70, compared to 8.03M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.72% and a Short% of Float of 2.85%.
Earnings Estimates
Its stock is currently analyzed by 4 different market analysts. On average, analysts expect EPS of $0.05 for the current quarter, with a high estimate of $0.07 and a low estimate of $0.04, while EPS last year was -$0.03. The consensus estimate for the next quarter is $0.07, with high estimates of $0.08 and low estimates of $0.05.
Analysts are recommending an EPS of between $0.32 and $0.25 for the fiscal current year, implying an average EPS of $0.28. EPS for the following year is $0.5, with 4 analysts recommending between $0.51 and $0.48.
Revenue Estimates
4 analysts predict $77.27M in revenue for the current quarter. It ranges from a high estimate of $79.7M to a low estimate of $76M. As of the current estimate, Adma Biologics Inc’s year-ago sales were $56.91M, an estimated increase of 35.80% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $81.27M, an increase of 35.20% less than the figure of $35.80% in the same quarter last year. There is a high estimate of $83M for the next quarter, whereas the lowest estimate is $78.4M.
A total of 4 analysts have provided revenue estimates for ADMA’s current fiscal year. The highest revenue estimate was $337M, while the lowest revenue estimate was $331.9M, resulting in an average revenue estimate of $333.87M. In the same quarter a year ago, actual revenue was $258.21M, up 29.30% from the average estimate. Based on 4 analysts’ estimates, the company’s revenue will be $389.87M in the next fiscal year. The high estimate is $395.5M and the low estimate is $383.5M. The average revenue growth estimate for next year is up 16.80% from the average revenue estimate for this year.
